Federal grants to Larix Bioscience LLC
Larix Bioscience LLC in Sunnyvale, California received $3.7 million in federal grants from fiscal 2021 to 2025, across 12 awards. Its largest program was Cardiovascular Diseases Research, with $747,462. It had no new grant money in fiscal 2025.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$3.7 million
- Awards12
- Awarded in FY 2025$0
- Largest award$599,638
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 3 | $754,016 |
| FY 2022 | 5 | $1.5 million |
| FY 2023 | 4 | $1.1 million |
| FY 2024 | 1 | $299,773 |
| FY 2025 | 0 | $0 |
Programs that fund Larix Bioscience LLC
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 3 | $747,462 |
| Child Health and Human Development Extramural Research | 2 | $685,847 |
| Aging Research | 2 | $620,405 |
| Allergy and Infectious Diseases Research | 1 | $599,638 |
| Arthritis, Musculoskeletal and Skin Diseases Research | 1 | $285,766 |
| Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention | 1 | $275,766 |
| Mental Health Research Grants | 1 | $259,606 |
| Cancer Treatment Research | 1 | $252,282 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 12 | $3.7 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Silencing autoantibody secretion for sle therapy - silencing autoantibody secretion for sle therapy abstract systemic lupus erythematosus (SLE) is a chronic and often life-threatening multisystem autoimmune disorder characterized by autoantibody production and immune-complex–mediated tissue damage. | Allergy and Infectious Diseases Research | May 8, 2023 | $599,638 |
| Advancing a novel therapy for preeclampsia - advancing a novel therapy for preeclampsia abstract preeclampsia (PE) is a serious complication of pregnancy manifested by high blood pressure, proteinuria, and edema, sometimes with encephalopathy, seizures, and hepatic failure. Pe complicates from 5 to | Child Health and Human Development Extramural Research | September 1, 2022 | $385,000 |
| Improved carnosic acid congener compounds for alzheimer?s disease - improved carnosic acid congener compounds for alzheimer’s disease abstract five million americans currently suffer the devastating consequences of alzheimer’s disease (AD), and unfortunately, the numbers are increasing due to our ag | Aging Research | September 24, 2022 | $326,205 |
| Therapeutic antibody for hyperemesis gravidarum - therapeutic antibody for hyperemesis gravidarum abstract hyperemesis gravidarum (HG), a syndrome of pregnancy involving extreme nausea and vomiting, affects 0.3- 2% of pregnancies. Hg is a major cause of hospital admissions during pregnancy and is as | Child Health and Human Development Extramural Research | September 19, 2022 | $300,847 |
| Overcoming pressure ulcers with engineered hormones and stem cells - abstract pressure ulcers (PUS) are a common and painful health condition, particularly among people who are elderly or physically impaired. Pus can affect at least 3 million adults in the U.S. And lead to more than 60,000 patients | Aging Research | September 15, 2023 | $295,923 |
| Therapy for ectopic calcification in pseudoxanthoma elasticum - therapy for ectopic calcification in pseudoxanthoma elasticum abstract pseudoxanthoma elasticum (PXE) is a rare monogenic disease that leads to ectopic calcification of the eyes, skin, and vasculature. Pxe results from loss-of-function | Arthritis, Musculoskeletal and Skin Diseases Research | September 21, 2023 | $285,766 |
| PA21-259, phs 2021-2 omnibus solicitation of the NIH, CDC and fda for small business innovation research grant applications (parent sbir [R43/R44] clinical | Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention | September 9, 2022 | $275,766 |
| Therapeutic antibody for anorexia nervosa - therapeutic antibody for anorexia nervosa abstract anorexia nervosa (AN) is a psychiatric condition characterized by changes in eating habits eventually leading to weight loss of more than 15% and up to 85% in comparison to a healthy population. The natura | Mental Health Research Grants | February 22, 2022 | $259,606 |
| Therapeutic antibody for cancer-associated cachexia - therapeutic antibody for cancer-associated cachexia abstract cachexia is a debilitating, wasting disease, characterized by loss of appetite, skeletal muscle, and fat mass. Cancer-associated cachexia constitutes a major unmet medical need, as 80% | Cancer Treatment Research | July 13, 2021 | $252,282 |
| Novel therapy for myocardial ischemia-reperfusion injury - novel therapy for myocardial ischemia-reperfusion injury abstract prompt restoration of the blood supply to the heart is considered the most effective treatment for acute myocardial infarction. However, reperfusion itself may aggravate the e | Cardiovascular Diseases Research | June 21, 2021 | $252,000 |
Questions people ask
How much federal grant money does Larix Bioscience LLC get?
$3.7 million in 12 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Larix Bioscience LLC the most?
The Department of Health and Human Services, with $3.7 million in 12 awards.
What is Larix Bioscience LLC's largest federal grant?
$599,638 under Allergy and Infectious Diseases Research, with its first action in the period on May 8, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Larix Bioscience LLC?
Its largest are Cardiovascular Diseases Research, Child Health and Human Development Extramural Research and Aging Research.
Other grant recipients in Sunnyvale
- Eridan Communications Inc
- Antora Energy, Inc.
- City of Sunnyvale
- Acellent Technologies Inc
- Petcoil, Inc
- Resurge International
- Insight M Inc.
- SC Solutions, Inc.
Largest federal grant recipients in California · Federal grants in California